Cure8 research brief
The gut microbiota–metabolism axis is implicated in IBD inflammation and barrier damage; probiotics that restore key metabolic pathways might offer a safe adjunctive strategy to help reduce inflammation and support remission.
Patients with IBD, clinicians treating IBD, researchers working on the microbiome or metabolic pathways in gut disease.
This review summarizes evidence linking gut microbiota metabolic pathways—short-chain fatty acids, bile acids, and tryptophan metabolism—to intestinal barrier function and mucosal immunity in IBD, and it describes how several probiotics (Clostridium butyricum, Escherichia coli, Faecalibacterium prausnitzii, Bifidobacterium, Limosilactobacillus reuteri) may modulate those pathways.
The authors present mechanistic rationale and clinical evidence suggesting probiotics can help refill depleted metabolic pathways, support barrier repair, and reduce inflammation as an adjunctive (not replacement) approach to standard IBD treatments.
The article is a systematic review intended to guide future mechanistic research and clinical use of probiotics in IBD. Practical takeaways are framed as research and clinical-reference points rather than treatment recommendations; the review supports further study and cautious clinical consideration of probiotics as adjunctive therapy.
This article is a systematic review (abstract-level content provided). It compiles mechanistic and clinical studies but does not itself provide new trial results; clinical application should rely on corroborating high-quality trials.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Researchers are exploring a way to deliver biologic drugs directly in the gut using engineered B cells that become long-lived plasma cells. If successful, this could allow sustained, localized anti-inflammatory protein...
The study suggests that in some people with IBD who have Candida overgrowth, systemic antifungal therapy (fluconazole) can change gut microbes and metabolites in ways linked to better disease activity over 8 weeks. That...
If successful, this approach could lower costs and simplify storage/transport of an established IBD antibody (adalimumab) and enable oral delivery, which would be relevant to people with Crohn’s disease or ulcerative...
